Raffles Medical (BSL.SI, SES) S$1.02 intraday ahead of 18 Feb 2026 earnings: 1.09 forecast

The BSL.SI stock is trading at S$1.02 in the Singapore (SES) intraday session as investors position ahead of Raffles Medical Group Ltd’s earnings due 18 Feb 2026. Volume sits at 221,800 shares versus a 50-day average of 1,423,060. Key numbers to watch in the upcoming report include EPS S$0.03, PE 34.00, and margins. This earnings spotlight shows why near-term revenue mix, hospital admissions and China/Vietnam outpatient growth will drive the stock move.

BSL.SI stock: Earnings calendar and what to expect

Raffles Medical (BSL.SI) will report results on 18 Feb 2026. The market will focus on revenue growth, margin trends and guidance. Management commentary on hospital services and overseas clinics matters for near-term cash flow.

Investors should watch operating cash flow per share of 0.06 and free cash flow per share of 0.05. Any change to dividend signals will move the price quickly in the SES session.

BSL.SI stock: Recent financials and performance metrics

Latest trailing twelve months show EPS 0.03, revenue per share 0.41, and net income per share 0.03. Net profit margin stands at 8.33% and gross margin at 45.56%. These figures frame the earnings beat or miss.

Raffles’ balance sheet is conservative: debt to equity 0.08 and cash per share 0.18. Market cap is S$1,881,692,507 and current ratio 1.19, which supports dividend coverage but limits aggressive buybacks.

BSL.SI stock: Valuation, Meyka grade and analyst context

Valuation metrics show PE 34.00, PB 1.86, and P/S 2.46. These indicate a premium to some regional peers but align with steady healthcare cash flows. Price to free cash flow ratio is 19.23, reflecting modest FCF yield.

Meyka AI rates BSL.SI with a score out of 100: 69.43 (Grade B, HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. Grades are informational and not financial advice.

BSL.SI stock: Technicals and trading signals for intraday

Intraday range is S$1.01–1.02 with a 50-day average price S$1.01 and 200-day average S$1.00. RSI is 58.60, ADX 38.14 indicating a firm trend, and CCI 114.48 suggesting short-term overbought conditions.

Volume is light at 221,800 versus average 1,423,060, so earnings-driven swings may be amplified. Traders should watch the Bollinger band upper S$1.02 and support near S$0.98.

BSL.SI stock: Forecasts, price targets and Meyka AI outlook

Meyka AI’s forecast model projects monthly S$1.10, quarterly S$1.16 and yearly S$1.09. Compared with the current price of S$1.02, the yearly forecast implies +6.86% upside. Forecasts are model-based projections and not guarantees.

Analyst sentiment and consensus remain mixed. The company’s recent DCF score is strong, but PE concerns persist. For more data, see the competitor compare on Investing.com source 1 and further sector peers source 2.

BSL.SI stock: Risks, catalysts and what could move the price

Upside catalysts include stronger-than-expected hospital admissions, improved outpatient growth in Greater China and Vietnam, and margin recovery. A positive guidance lift could push price above the year high S$1.09.

Risks include slower elective procedures, margin compression from higher staff costs, and weaker cash flow. Market liquidity is low, so sharp intraday moves are possible around the earnings release. See the Meyka stock page for quick reference Meyka stock page.

Final Thoughts

Key takeaways on the BSL.SI stock heading into the 18 Feb 2026 earnings: the name trades at S$1.02 with PE 34.00 and conservative leverage. Meyka AI’s forecast model projects a yearly target of S$1.09, implying +6.86% upside versus today. The Meyka grade of 69.43 (B, HOLD) reflects steady fundamentals, solid cash flow yield ~5.20%, and mixed growth signals. Short-term movers will be margins, hospital admissions and commentary on overseas clinic expansion. Traders should note light liquidity and technical overbought signals like CCI 114.48. Forecasts are model-based projections and not guarantees. Use results and guidance to re-evaluate position sizes and stop-loss levels in SGD before market close.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.